Replimune's SWOT analysis: biotech firm's stock poised for growth in oncology
Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment with a current market capitalization of $803 million, has been making ...